Indications des bisphosphonates dans les affections osseuses autres que l’ostéoporose
Mots-clés :
Bisphosphonates, métastases osseuses, ostéolyse maligne, dysplasie fibreuse, maladie de Paget, ostéogenèse imparfaite, ostéolyse maligne, algodystrophie, ostéonécrose aseptique, résorption osseuseRésumé
But : Rapporter les indications des affections osseuses autres que l'ostéoporose.
Méthodes : Revue narrative de la littérature.
Résultats : Les bisphophonates représentent une nouvelle modalité thérapeutique dont le champ d’application est en train de s’élargir.
Outre l’ostéoporose, les bisphosphonates trouvent leur indication de première intention dans différentes pathologies osseuses représentées essentiellement par la maladie de Paget et les ostéolyses malignes.
L’efficacité des bisphosphonates a été prouvée également dans d’autres pathologies : telle que la dysplasie fibreuse et l’ostéogénèse imparfaite. Par ailleurs des études sont en cours afin d’évaluer l’efficacité des bisphosphonates dans le traitement de l’algodystrophie, la perte osseuse au cours des rhumatismes inflammatoires chroniques en dehors d’un traitement cortisonique et au cours de l’ostéonécrose aseptique.
Conclusion : Les Bp puissants inhibiteurs de la résorption osseuse, d’abord utilisés dans le traitement de l’ostéoporose qui demeure leur principale indication, ont démontré leur efficacité dans la maladie de Paget, les hypercalcémies malignes et les complications osseuses des ostéolyses malignes.
Téléchargements
Références
Stresing V, Daubine F, Benzaid I, Mönkkönen H, Clézardin P. Bisphosphonates in cancer therapy. Cancer Lett. 2007; 257: 16-35.
Tubiana-Hulin M. Les bisphosphonates dans le traitement des métastases osseuses des tumeurs solides. Rev du Rhum 2002; 69: 1010-1
Chapurlat R, Meunier P.J. Bisphosphonates et remodelage osseux : efficacité dans la maladie de Paget, la dysplasie fibreuse et l'ostéoporose. Rev chir orthop 1998; 84: 743
4- Orcel P, Beaudreuil J. Les bisphosphonates en dehors de l'ostéoporose. Rev Rhum 2002; 69: 20-9
Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997; 98: 665-72.
Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001; 61: 4418-24.
Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992; 340: 1049-52.
Heim M.E, Clemens M.R, Queisser W. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: a multicenter study. Oncologie 1995; 18: 439-48.
Brincker H,Westin J, Abildgaard N et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma : a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. Br J Haematol 1998; 101: 280-86.
Berenson R, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J M 1996; 334: 488-93.
Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846-54
Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996; 19: 663-7.
Diel IJ, Solomayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J M 1998; 339: 357-63.
Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and its effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88: 1082-90.
Saad F. Bisphosphonates can prevent skeletal complications of malignant bone disease from prostate cancer and renal cell carcinoma. Europ urolo suppl 2007; 6: 683-8
Kurth AA. Optimizing outcomes: experience with ibandronate in metastatic bone disease and bone pain Ibandronate: An effective treatment for metastatic bone pain. European J of Cancer 2006; 4: 9-12.
Body JJ. Tumor bone disease. Ann Endocrino 2006; 67: 166-72.
Meunier PJ, Coindre J, Edouard CM, Arlot ME. Bone histomorphometry in Paget's disease: quantitative and dynamic analysis of pagetic and non pagetic bone tissue. Arthritis Rheum 1980; 23: 1095¬-103.
Meunier PJ, Salson C, Mathieu L et al. Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop 1987; 217: 37¬44.
Saraux A, Brun-Strang C, Mimaud V, Vigneron AM, Lafuma A. Epidemiology, impact, management, and cost of Paget's disease of bone in France. Joint Bone Spine 2007; 74: 90-5
Delmas PD, Meunier PJ. Treatment of Paget's disease of bone. N Engl J Med 1997; 336: 558-66.
Mc Lung MR, Tou CK, Goldstein NH, Picot C: Tiludronate therapy for Paget's disease of bone. Bone 1995; 17: 493-6.
Roux C, Gennari C, Farrerons J et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 1995; 38: 851-8.
Gutteridge DH, Ward LC, Stewart GO et al. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res 1999; 14: 79-84.
Selby PL. Pamidronate in the treatment of Paget's disease. Bone 1999; 24: 57-8.
Grauer A, Heichel S, Knaus J, Dosch E, Ziegler R. Ibandronate treatment in Paget's disease of bone. Bone 1999; 24: 87-9
Orcel P, Rousière M. Maladie de Paget, prise en charge thérapeutique. Press Med 2005; 34 : 612-6.
Miller P, Brown J, Hosking D et al. Zoledronic acid produces higher and more rapid therapeutic response rates versus risedronate in patients with Paget's disease. Osteoporos Int 2004; 15: 509.
Liens D, Delmas PD, Meunier PJ: Long¬term effects of pamidronate in fibrous dysplasia. Lancet. 1994; 343: 953-4.
Chapurlat RD, Delmas PD, Meunier PJ: Extended follow¬up of patients with fibrous dysplasia of bone treated with pamidronate. Bone 1998; 23: 56.
Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J M 1998; 339: 947-52.
D'Eufemia P, Finocchiaro R, Zambrano A, Tetti M, Ferrucci V, Celli M. Reduction of plasma taurine level in children affected by Osteogenesis Imperfecta during bisphosphonate therapy. Biomed Pharmacother 2007; 6: 235-40.
Berthelot JM. Actualités dans le traitement des algodystrophies (syndrome douloureux régional complexe de type I). Rev Rhum 2006; 73: 881-86.
Cortet B, Flipo RM, Coquerelle P, Duquesnoy B, Delcambre B. Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy and safety of the second generation bisphosphonate pamidronante. Clin Rheumatol 1997; 16: 51-6.
Varenna M, Zucchi F, Ghiringhelli D et al. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double-blind, placebo controlled study. J Rheumatol 2000; 27: 1477-83.
Manicourt DH, Brasseur JP, Boutsen Y, Depreseux G, Devogelaer JP. Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. Arthritis Rheum 2004; 50: 3690-7.
Breuil V, Euller-Ziegler L. Polyarthrite rhumatoïde et bisphosphonates. Rev Rhum 2006; 73 : 659-64
Cantatore F.P, Acquista C.A, Pipitone V. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 1999; 26: 2318-23.
Valleala H, Laasonen L, Koivula MK et al. Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol 2003; 30: 468-73.
Eggelmeijer F, Papapoulos SE, Van Paassen HC, Dijkmans BA, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 1994; 21: 2016-20.
Eggelmeijer F, Papapoulos SE, Van Paassen HC et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 1996; 39: 396-402.
Breuil V, Euller-Ziegler L.Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 2006; 73: 349-54.
Toussirot E, Ricard-Blum S, Dumoulin G, Cedoz J.P, Wendling D. Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatol 1999; 38: 21-7.
Maksymowych WP, Lambert R, Jhangriet GS et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001; 28: 144-55.
Kim Harry KW, Sanders M, Athavale S, Bian H, Bauss F. Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infarcted femoral head. Bone 2006; 39: 205-12.
Agarwala S, Jain D, Joshi VR, Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective penlabel study. Rheumatology 2005; 44: 352-9.
Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Jt Surg Am 2005; 87: 2155-9.
